Adlyxin/lixisenatide Cost, Side effects, Dosage, Uses for Type 2 Diabetes

Adlyxin is manufactured by Sanofi-Aventis U.S. LLC, of Bridgewater, New Jersey.

Adlyxin with an active ingredient lixisenatide is the new drug approved by U.S. Food and Drug Administration on July 28, 2016. This drug is approved in parentral dosage form. It's dosage frequency is once a day and injected through subcutaneous route. Adlyxin/lixisenatide belongs to a class of drug called as a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is hormone that helps in the regulation of blood sugar control.

Type 2 diabetes is a common problem in US population. In type 2 diabetes, insulin produces at normal level but insulin sensing receptors present in liver, kidney and other organ tissues become desensitize. This desensitization leads to improper or poor attachment of insulin at insulin bind receptors. Ultimately, patient loses his control over blood sugar and becomes diabetic.

Adlyxin is aimed to improve blood  sugar level along with exercise and dietary control because no single pill can efficiently control blood sugar control without taking further measures. Type 2 diabetes is a kind of disease that can be managed by taking medications along with life style modifications.

During clinical trails Adlyxin safety profile was quite satisfactory. Adlyxin is quite safe for patient having types 2 diabetes along with atheroseclerosis ( stenosis of arteries).  Adlyxin helps to improve blood sugar level with no harm to cardiac issues like angina, atrial fibrillation, tachycardia, thromboembolic phenomenon and atherosclerosis.

Adlyxin/lixisenatide Cost, Side effects, Dosage, Uses for Type 2 Diabetes


Adlyxin/lixisenatide Side effects


Adlyxin was tested for possible side effects during clinical trials. These side effects were mild moderate.
  • Nausea
  • Vomiting
  • Headache
  • Diarrhea
  • Dizziness
  • Hypersensitivity
  • Anaphylaxis
  • Asthenia
  • Muscle Weakness
  • Mild Fever
  • Rash at injection site
  • Loss of appetite 
 According to data received from clinical trials, Adlyxin does not have life threatening or lethal side effects.


 Adlyxin/lixisenatide Uses/Prescribing Information 

US FDA approved Adlyxin to control blood sugar level in type 2 diabetes. Adlyxin gives better control over blood sugar level if it used with other diabetes medications following life style modifications and dietary restrictions.

However, this drug was also tested as standalone therapy during clinical trials in which it is showed promising results. Adlyxin should not be used to treat people with type 1 diabetes or patients with increased ketones in their blood or urine (diabetic ketoacidosis).


 Adlyxin/lixisenatide Cost and Dosage

According to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.

Xiidra/lifitegrast Cost, Side effects, Dosage, Uses for Dry eye

Xiidra is manufactured by Shire US Inc., of Lexington, Massachusetts.

FDA has approved a new drug having active ingredient lifitegrast with brand name of Xiidra for the treatment of dry eye disease. This drug belongs to class termed as lymphocyte function-associated antigen 1 (LFA-1) antagonist. This is first kind of drug of its class approved for the treatment of dry eye disease. This drug is presented to FDA in the form of ophthalmic solution and marked as prescription only medicine.

Dryness of eyes is a common problem in elder people due to decrease activity of tears gland. Dryness of eye itself does cause any harm or damage to eye but it increases the risk of eye ulcer, corneal injury, difficulty in blinking, vision problem etc. About 5% of individuals having age 30 to 40 years have problem of dryness of eyes while people with age more than 65 years have 10% occurrence rate.

Most common reasons of eye dryness is inadequate production of tears or low consistency of ophthalmic fluid. These problem may arise due to extreme weather conditions like extreme hot or cold weather or too much air pressure.

About 1100 individuals were selected to assess the clinical efficacy and safety profile of Xiidra/lifitegrast. It shows satisfactory results in four randomized controlled clinical trials. During these clinical trials patients received lifitegrast eyedrops or placebo eyedrops twice daily 12 hours apart for 12 weeks.

 Xiidra/lifitegrast Cost, Side effects, Dosage, Uses for Dry eye


Xiidra/lifitegrast Side Effects

During clinical trials most common side effects observed were mild to moderate but there was no evidence of serious kind of side effects. Some common side effects were

  • Eye irritation
  • Blurred vision
  • Discomfort
  • Dysgeusia (Feeling unusual taste)
  • Headache
  • Burning sensation

Xiidra/lifitegrast Uses or Prescribing Information

FDA approved Xiidra/lifitegrast for treatment of dryness of eye in ophthalmic dosage form. Tin his drug is marked as prescription only medicine so you need a valid prescription in order to get this medicine.

Xiidra/lifitegrast Cost

This drug was presented to FDA in ophthalmic dosage form with potency of  5% ophthalmic solution. Xiidra is now available in market with pack size of 60's. According to market survey initial cost of one box is about 400$ - 500$ that contains 60 ampules. This approximate cost may variate with the passage of time so, we will update you accordingly.

Xiidra/lifitegrast Dosage

In adults, usual dosage frequency of xiidra is one drop into each eye after every 12hrs for 3-5 days depending upon the severity of disease. In children, xiidra safety profile has not yet evaluated.

Epclusa Cost, Side effects, Dosage, Uses for Hepatitis C infection

Epclusa is manufactured and marketed by Gilead Sciences, Inc., of Foster City, California.

Epclusa  is first kind drug approved by US FDA for the treatment of all six major HCV genotypes. Epclusa contains combination of sofosbuvir, a drug approved by FDA as break through therapy for HCV and  velpatasvir, a new drug, and is the first to treat all six major forms of HCV.

US FDA approved this drug on July 28 2016 for the treatment of chronic type of hepatitis in adult patients with cirrhosis or without cirrhosis. If liver cirrhosis progresses to advance stage then Epclusa is used with antiviral drug called as ribavirin.

Hepatitis C is a viral infection leads towards liver cirrhosis if it persists for a long term. HCV virus has 6 genotypes 1 to 6. Each genotype requires duration of therapy and in some cases therapy may also be changed. In United States about 75% people have genotype 1 that means genotype 1 is the most common type in United States of America. Genotype 2 has prevalence rate of 25%. Other genotypes are less common and only few patients are diagnosed with such kind of genotypes.

Epclusa Cost, Side effects, Dosage, Uses for Hepatitis C infection
Epclusa Cost, Side effects, Dosage, Uses for Hepatitis C infection


Epclusa Side effects


There are two types of side effects that were observed during Epclusa clinical trials like moderate and severe type of side effects.

Moderate Side effects include  
  • Fatigue
  • Headache
  • Nausea 
  • Vomiting
  • Dizziness
  • Dry Cough
  • Fever
  • Myalgia
  • Stomach discomfort
  • Dryness
Severe Side effects include

  • Bradycardia 
  • Hypersensitivity
  • Cardiac arrhythmia 
Epclusa may interact with some other drugs for example it should not be used with amiodarone due to increase cardiac risks like rapid fluctuations in heart rate, severe bradycardia and cardiac arrest. Some drugs may reduce the serum level of epclusa which will reduce the efficacy of drug.

Epclusa Uses or Prescribing Information


Epclusa is prescribed for the treatment of chronic HCV infection in adults having liver cirrhosis or do not have liver cirrhosis. It indicated for all kinds of HCV genotypes because it contains combination of drugs. Up-till now, Epclusa is only regimen to treat all six major HCV genotypes effectively.

Epclusa Cost


This drug is presented to FDA in tablet form (oral dosage form) with potency 400mg/100mg (Sofosbuvir 400mg and velpatasvir 100mg). According to market survey price of epclusa is variable but approximate average cost of one pack of epclusa ranges between 24,000$ - 26,000$. One pack of epclusa contains 28 tablets ( 28's pack size).  This approximate cost may also variate with the passage of time so, we will update you accordingly.

Epclusa Dosage

This drug is indicated for chronic hepatitis C in adults with genotype 1,2,3,4,5 and 6. According to clinical data provided by health authorities the dosage frequency is once a day through oral route (PO). Duration of therapy depends upon patient liver condition and genotype. However, average duration of therapy is between 4-6 months. This drug my be used in combination with other antiviral drugs for targeted therapy.

Ocaliva/obeticholic acid Cost, Side effects, Dosage, Uses in primary biliary cholangitis

Ocaliva is manufactured by New York, New York-based Intercept Pharmaceuticals, Inc.

Food and Drug Administration has approved Ocaliva that contains active ingredient obeticholic acid for the treatment of primary biliary cholangitis (PBC). FDA proposed this drug  to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to ursodeoxycholic acid, or as a single therapy in adults unable to tolerate UDCA.

Ocaliva, given orally, ties to the farnesoid X receptor (FXR), a receptor found in the core of cells in the liver and digestive system. FXR is a key controller of hepatic metabolic pathways. Ocaliva expands bile stream from the liver and stifles bile acid creation in the liver, in this way decreasing the exposure of the liver to lethal levels of biliary contents.

PBC is an chronic, or long lasting, illness that causes blockage of biliary system in the liver to end up kindled, harmed and at last pulverized. This causes bile to stay in the liver, which harms the liver cells after some time, and results in cirrhosis, or scarring of the liver. As cirrhosis advances, and the measure of scar tissue in the liver expands, the liver loses its capacity to work.
Ocaliva/obeticholic acid Cost, Side effects, Dosage, Uses in primary biliary cholangitis
Ocaliva/obeticholic acid Cost, Side effects, Dosage, Uses in primary biliary cholangitis

Ocaliva Side effects

The most common side effects of Ocaliva are

  • Pain in the middle part of the throat (oropharyngeal)
  • Severe itching of the skin (pruritus)
  • Abdominal pain and discomfort
  • Generalized weakness
  • Joint pain (arthralgia)
  • Fatigue
  • Dizziness
  • Constipation
  • Headache
  • Mild fever

Ocaliva should not be used in patients with complete biliary obstruction.

Ocaliva Uses or Prescribing information 

Patients left untreated, or who have not reacted to ursodeoxycholic acid, are at danger for liver cirrhosis and death. Ocaliva gives a vital treatment choice to patients living with initial biliary cholangitis who have not responded to the main other affirmed treatment, ursodeoxycholic acid.

Ocaliva is reserved for the treatment of initial biliary cholangitis in combination with ursodeoxycholic acid in grown-ups with a deficient response to ursodeoxycholic acid, or as a solitary treatment in grown-ups not able to endure ursodeoxycholic acid.

Ocaliva Cost

According to market survey average cost of 30 ocaliva tablets with potency of 5mg is approximately 5840$ to 5890$. Similarly 30 ocaliva talets with potency of 10mg is approximately 6000$ to 6250$. This cost may vary due to number of factors like location, discount policy or coupon system. Ocaliva is now available in two pack size 30's and 90's.

Ocaliva Dosage

Ocaliva is available in two potencies 5mg and 10mg. Usual dose of ocaliva at startup is 5mg orally every day. If it does not give adequate response after taking 2-3 weeks then dose may titerate up-to 10mg once a day. Dose should not be exceed 10mg/day.

Zinbryta/daclizumab Cost, Side effects, Uses, Dosage for multiple sclerosis

Zinbryta is manufactured by Biogen, Inc. of Cambridge, Massachusetts.

The U.S. Food and Drug Administration has been approved Zinbryta that contains active ingredient daclizumab for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta belongs to a class termed as monoclonal antibodies. Zinbryta is presented in parentral dosage form and categorized as long acting agent.

Zinbryta should be reserved for  those patients who have had a deficient response to combination therapy for multiple sclerosis (MS) on the grounds that Zinbryta has genuine dangers including liver damaging effects and modulation of immune system. In light of the dangers, Zinbryta has a boxed cautioning and is accessible just through a limited circulation program under a risk Evaluation and mitigation Strategy.

MS is a chronic, provocative, immune system malady of the focal sensory system that disturbs the co-ordination between the spinal region and different parts of the body. It is among the most widely recognized reasons for neurological disability in adults and happens more often in ladies than men. For the vast majority with MS, episodes of worsening function (relapses) are initially followed by recovery periods (remissions).


Zinbryta Side effects

The most common adverse reactions that wrere observed during Zinbryta therapy are
  • Cold symptoms (nasopharyngitis)
  •  Increased alanine aminotransferase
  • Throat (oropharyngeal) pain
  • Enlargement of lymph nodes
  • Upper respiratory tract infection
  • Rash
  • Influenza
  • Dermatitis
  • Eczema
  • Depression

 Zinbryta Uses or prescribing information

Due to serious side effects produced by Zinbryta it should be reserved for those patients who have had a deficient response to combination therapy for multiple sclerosis (MS) or relapsing forms of multiple sclerosis (MS)

The viability of Zinbryta was appeared in two clinical trials. One trial conducted at Zinbryta and Avonex in 1,841 members who were studied for 144 weeks. Patients on Zinbryta had less relapses than patients taking Avonex.

The second trial was conducted between Zinbryta and inactive agent (placebo) and included 412 members who were dealt with for 52 weeks. In that study, those accepting Zinbryta had less relapses as compared with those getting inactive agent.

Zinbryta Cost

This drug is now available in market in a single-dose prefilled syringe with potency of 150mg/ml. According to market survey initial price of a single-dose prefilled syringe of zinbryta costs about 7000$ - 7600$. This approximate cost may variate with the passage of time so, we will update you accordingly.

Zinbryta Dosage

In adults, usual dosage frequency of zinbryta is 150mg subcutaneously (SC) once in a month in case of recurrent episodes of multiple sclerosis. Dose titration may be required in case of liver impairment. In children, safety profile of zinbryta/daclizumab has not yet evaluated.

Tecentriq/atezolizumab Cost, Side effects, dosage, Uses for bladder cancer

Tecentriq is marketed by Genentech based in San Francisco, California. The Ventana PD-L1 (SP142) assay complementary diagnostic for Tecentriq is marketed by Ventana Medical Systems, based in Tucson, Arizona.

Tecentriq acts on the PD-1/PD-L1 pathway (proteins found on the body's immune cells and some tumor cells). By blocking these co-ordinations, Tecentriq may help the body's defense system to cope with tumor cells. Tecentriq is the first FDA-affirmed PD-L1 inhibitor and the most recent in the broader class of PD-1/PD-L1 agent endorsed by the FDA in previous two years.

Tecentriq is reserved for the treatment of patients with locally progressed or metastatic urothelial carcinoma whose disease has became more severe after continuous administration of platinum-containing chemotherapy, or within range of 12 months of getting platinum-containing chemotherapy, either before (neoadjuvant) or after (adjuvant) surgical treatment. Urothelial carcinoma has high prevalence rate as compared to other type of bladder cancer. It takes place in the urinary system and spreads rapid to surrounding organs.




Tecentriq/atezolizumab Side effects

The safety and efficacy of Tecentriq were studied in a single-arm clinical trial involving 310 patients with locally advanced or metastatic urothelial carcinoma. Most common side effects that were observed during therapy are 
  • Urinary tract infection,
  • Decreased appetite, 
  • Nausea, 
  • Constipation
  • Fatigue,
  • Fever (pyrexia) 
  • Increased risk of infection 
  • Changes in immune system response
  • Rashes
  • Hypersensitivity

Tecentriq/atezolizumab Uses or Indications

FDA approved tecentriq/atezolizumab for the treatment of progressive or advance urothelial carcinoma. This drug is also indicated for those who have became more severe after continuous administration of platinum-containing chemotherapy, or within range of 12 months of getting platinum-containing chemotherapy, either before (neoadjuvant) or after (adjuvant) surgical treatment.

Tecentriq/atezolizumab Cost

This drug is administered by your healthcare practitioner (HCP), which usually means:
  • It may comes under special items category.
  • You cannot fill this prescription in a regular pharmacy. Your doctor, hospital, or clinic will provide this  medication because of possible complications or other issues.
  • This drug is likely to be covered under your medical benefit if you have insurance.

Tecentriq/atezolizumab Dosage

The usual dosage of tecentriq/atezolizumab is 1200 mg IV q3wk at rate 60min per infusion. This dosage frequency may be titrated in case of toxicity or increase the dosage in special instances to slow down the progression. 

Nuplazid/pimavanserin Cost, Side effects, Dosage, Prescribing Info

Nuplazid is marketed by Acadia Pharmaceuticals Inc. of San Diego, California.

 The U.S. Food and Drug Administration approved Nuplazid containing active ingredient pimavanserin in tablet dosage form for the treatment of hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s disease.

Nuplazid was granted breakthrough therapy designation for the treatment of hallucinations and delusions associated with Parkinson’s disease. Breakthrough therapy designation is a program designed to expedite the development and review of drugs that are intended to treat a serious condition and where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint.

The neurological issue normally happens in individuals over age 60, when cells in the cerebrum that deliver a compound called dopamine get to be impeded or pass on. Dopamine transmits signals between the zones of the brain that create smooth development - like eating, composing and shaving.

Early indications of the ailment are unpretentious and happen step by step. In some individuals Parkinson's illness advances more rapidly than in others. As the ailment advances, the shaking, or tremor, which influences many individuals with Parkinson's sickness, may start to meddle with every day activities. Different side effects may incorporate despondency and other passionate changes; mind flights and fancies; trouble in gulping, biting, and talking; urinary issues or stoppage; skin issues; and difficulty in sleeping.


Nuplazid/pimavanserin Cost, Side effects, Dosage, Prescribing Info

Nuplazid/pimavanserin Side effects

Likewise with other atypical antipsychotic drugs, Nuplazid has a Boxed Warning cautioning medicinal services experts around an expanded danger of death connected with the utilization of these medications to treat more established individuals with dementia related psychosis. No medication in this class is affirmed to treat patients with dementia-related psychosis.

The most common side effects of nuplazid observed during clinical trials are
  • Swelling ankles, legs, and feet due to the accumulation of excessive fluid in the tissue
  • Nausea
  • Abnormal state of mind (confused state)
  •  Peripheral edema
  • Fever
  • Headache
  • Body pain

Nuplazid/pimavanserin Uses or Indications

Nuplazid containing active ingredient pimavanserin in tablet dosage form is used for the treatment of hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s disease.

Nuplazid/pimavanserin Cost

This drug is presented to FDA in tablet dosage for. According to market survey this drug is now available with pack size of 30 tablets (30's) and its potency is 17mg. Cost of each pack containing 30 tablets ranges from 990$ - 1030$. Few retail outlets may offer you discount on nuplazid pack if you give them nuplazid discount coupon.

Nuplazid/pimavanserin Dosage

Nuplazid is indicated for treatment of hallucinations and delusions associated with Parkinson disease psychosis. It's usual dosage for adults is 34 mg PO qDay (without titration). However, safety profile of nuplazid regarding its use in children has not yet established.

Venclexta/venetoclax Cost, Side effects, Uses for chronic lymphocytic leukemia

Venclexta is manufactured by AbbVie Inc. of North Chicago, Illinois, and marketed by AbbVie and Genentech USA Inc. of South San Francisco, California. The Vysis CLL FISH probe kit is manufactured by Abbott Molecular of Des Plaines, Illinois.

 Venclexta is indicated for daily use after detection of 17p deletion is confirmed through the use of the FDA-approved companion diagnostic Vysis CLL FISH probe kit. Venclexta is the first FDA-approved treatment that targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with CLL.

Chronic Lymphocytic Leukemia is one of the most common types of leukemia in adults, with approximately 15,000 new cases diagnosed each year. CLL is characterized by the progressive accumulation of abnormal lymphocytes, a type of white blood cell. Patients with CLL who have a 17p deletion lack a portion of the chromosome that acts to suppress cancer growth. This chromosomal abnormality occurs in approximately 10 percent of patients with untreated CLL and in approximately 20 percent of patients with relapsed CLL.

Venclexta/venetoclax Cost, Side effects, Uses for chronic lymphocytic leukemia


Venclexta/venetoclax Side effects

The most common side effects of Venclexta include

  • Low white blood cell count
  • Diarrhea
  • Nausea
  • Anemia
  • Upper respiratory tract infection
  • Low platelet count (thrombocytopenia)
  • Fatigue. 

Serious complications can include 

  • Pneumonia
  • Neutropenia with fever
  • Fever
  • Autoimmune hemolytic anemia
  • Anemia
  • Metabolic abnormalities known as tumor lysis syndrome. 
  • Live attenuated vaccines should not be given to patients taking Venclexta.

 Venclexta/venetoclax Uses

Venclexta is used for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy.

 Venclexta/venetoclax Cost

Venclexta is now available in market with potency of 10mg, 50mg and 100mg. Pack size of venclexta include 2's, 7's and 14's. Average cost of one pack of venclexta 10mg is 125$-130$.

 Venclexta/venetoclax Dosage

Venclexta dosing frequency may depend upon you condition and severity of disease. However standard dosing frequency is  20mg once a day for 1 week and then you may increase the potency of dose up-to 100mg with same frequency.

Cinqair/reslizumab Cost, Side effects, Uses for asthma

Cinqair is made by Teva Pharmaceuticals in Frazer, Pennsylvania.

Asthma is a chronic disease that causes inflammation in the airways of the lungs. During an asthma attack, airways become narrow making it hard to breathe. Severe asthma attacks can lead to asthma-related hospitalizations because these attacks can be serious and even life-threatening.

Cinqair is administered once every four weeks via intravenous infusion by a health care professional in a clinical setting prepared to manage anaphylaxis. Cinqair is a humanized interleukin-5 antagonist monoclonal antibody produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. Cinqair reduces severe asthma attacks by reducing the levels of blood eosinophils, a type of white blood cell that contributes to the development of asthma.

According to the Centers for Disease Control and Prevention, as of 2013, more than 22 million people in the U.S. have asthma, and there are more than 400,000 asthma-related hospitalizations each year.


This drug is presented to FDA in capsule dosage form but it’s potency and dosage frequency is difficult to evaluate until it appears in the market. So, we will update all the parameters of drug once, it gets available in the market.


Cinqair/reslizumab Side effects

Cinqair can cause serious side effects including
  • Allergic (hypersensitivity) reactions
  • Anaphylactic shock
These reactions can be life-threatening.

The most common side effects in clinical trials for Cinqair included anaphylaxis, cancer, and muscle pain.
  • Skin rash (hives)
  • Swelling of your face, lips, mouth, or tongue
  • Symptoms of low blood pressure (fainting, dizziness, light headache, confusion, fast heart beat)
  • Itching
  • Paleness
  • Flushing
  • Nausea or abdominal discomfort
  • Breathing problems

Cinqair/reslizumab Prescribing Information

Cinqair is approved for patients who have a history of severe asthma attacks (exacerbation's) despite receiving their current asthma medicines.

Cinqair/reslizumab Cost

This drug is administered by your healthcare practitioner (HCP), which usually means:
  • It may comes under special items category.
  • You cannot fill this prescription in a regular pharmacy. Your doctor, hospital, or clinic will provide this  medication because of possible complications or other issues.
  • This drug is likely to be covered under your medical benefit if you have insurance.

Cinqair/reslizumab Dosage 

Cinqair is administered by intravenous (IV) infusion according weight of body 3 mg/kg 1 time in every 4 weeks. This dose frequency and potency may be adjusted by your health care provider depending upon disease condition.

Taltz/ixekizumab Cost, Side effects, Uses for Psoriasis


Taltz is marketed by Indanapolis, Indiana-based Eli Lilly and Company.

Taltz is administered as an injection. It is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected), phototherapy (ultraviolet light treatment) or a combination of both.

Taltz’s active ingredient is an antibody (ixekizumab) that binds to a protein (interleukin (IL)-17A) that causes inflammation. By binding to the protein, ixekizumab is able to inhibit the inflammatory response that plays a role in the development of plaque psoriasis.

Psoriasis is a skin condition that causes patches of skin redness and flaking. Psoriasis is an autoimmune disorder that occurs more commonly in patients with a family history of the disease, and most often begins in people between the ages of 15 and 35. The most common form of psoriasis is plaque psoriasis, in which patients develop thick, red skin with flaky, silver-white scales.

Taltz/ixekizumab Cost, Side effects, Uses for Psoriasis

Taltz/ixekizumab  Side effects

  • Serious allergic reactions and development or worsening of inflammatory bowel disease have been reported with the use of Taltz. Monitor patients closely for these conditions. 
  • The most common side effects include upper respiratory infections, injection site reactions and fungal (tinea) infections.

Taltz/ixekizumab  Prescribing Information

US FDA has approved this medicine to treat adults with moderate-to-severe plaque psoriasis. 

Taltz/ixekizumab Cost and Dosage

This drug is presented to FDA in parental dosage form but it’s potency and dosage frequency is difficult to evaluate until it appears in the market. So, we will update all the parameters of drug once, it gets available in the market.